Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2020

View Archived Issues

MMA induces epithelial-to-mesenchymal transition

CAR T cells for inhibition

First healthy volunteers enrolled in phase I study of GRAd-COV2 COVID-19 vaccine candidate

Trevena initiates proof-of-concept study of TRV-027 in patients with COVID-19

BIIB-091: a potent, highly selective BTK inhibitor for the treatment of multiple sclerosis

GB-1211, first orally available galectin-3 inhibitor as potential treatment for NASH

Nicotinamide riboside suppresses inflammatory activation of PBMC in heart failure

Kyorin Pharmaceutical presents new 15-PGDH inhibitors

New DNA polymerase theta inhibitors discovered at Ideaya Biosciences

Foghorn Therapeutics patents PROTACs targeting BRD9

Canwell Biotech identifies new TLR7/8 agonists

New sphingomyelin phosphodiesterase 3 inhibitors discovered at Johns Hopkins University

Antifungal immunity helps out antibacterial vaccine

FDA clears IND for phase II study of RGX-314 for diabetic retinopathy

Immunogenicity of an saRNA lipid NP vaccine candidate encoding the SARS-CoV-2 S protein in mice

Topline data presented from phase II ELEKTRA study of soticlestat

AtlasMedx initiates phase I/II study of AMXI-5001 in advanced malignancies

Positive topline data from phase IIa trial of IMVT-1401 in myasthenia gravis

Mereo BioPharma initiates phase Ib/II study of alvelestat in COVID-19 respiratory disease

Phase III ASCEMBL study of asciminib in CML meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...